Evidence Generation Strategies Post-Inflation Reduction Act

This white paper discusses the impact of the Inflation Reduction Act (IRA) on evidence generation in the pharmaceutical industry. Following the IRA's passage in 2022, significant changes have occurred in how life science companies approach evidence generation to support product launches and pricing negotiations. The paper outlines key shifts, including a greater emphasis on patient-centricity, increased investment in real-world evidence generation, and strategic pricing and market access planning. It details how companies are engaging earlier with payers and regulatory agencies to align their evidence generation activities with stakeholder needs. The IRA introduces new pressures on pricing and market access, compelling manufacturers to adapt their strategies. The paper also highlights the IRA's three core initiatives that affect research and development, launch planning, and market access strategies, emphasizing the need for companies to prepare for a new reality in the biopharma landscape. Overall, the document serves as a guide for navigating the evolving regulatory environment and optimizing evidence generation efforts.